Bookbuilding IPO | ₹895 Cr | Listed at BSE, NSE
Sudeep Pharma IPO is a book build issue of ₹895.00 crores. The issue is a combination of fresh issue of 0.16 crore shares aggregating to ₹95.00 crores and offer for sale of 1.35 crore shares aggregating to ₹800.00 crores.
Sudeep Pharma IPO bidding started from Nov 21, 2025 and ended on Nov 25, 2025. The allotment for Sudeep Pharma IPO was finalized on Nov 26, 2025. The shares got listed on BSE, NSE on Nov 28, 2025.
Sudeep Pharma IPO price band is set at ₹593 per share. The lot size for an application is 25. The minimum amount of investment required by an retail is ₹14,825 (25 shares) (based on upper price). The lot size investment for sNII is 14 lots (350 shares), amounting to ₹2,07,550, and for bNII, it is 68 lots (1,700 shares), amounting to ₹10,08,100.
ICICI Securities Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Sudeep Pharma IPO RHP for detailed Information.
IPO Open
Fri, Nov 21, 2025
IPO Close
Tue, Nov 25, 2025
Issue Price
₹593 per share
Market Cap (Pre-IPO)
₹6,697.85 Cr
| IPO Date | 21 to 25 Nov, 2025 |
| Listed on | Fri, Nov 28, 2025 |
| Face Value | ₹1 per share |
| Price Band | ₹563 to ₹593 |
| Issue Price | ₹593 per share |
| Lot Size | 25 Shares |
| Sale Type | Fresh Capital & OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 1,50,92,749 shares (agg. up to ₹895 Cr) |
| Fresh Issue | 16,02,023 shares (agg. up to ₹95 Cr) |
| Offer for Sale | 1,34,90,726 shares of ₹1 (agg. up to ₹800 Cr) |
| Share Holding Pre Issue | 11,13,46,602 shares |
| Share Holding Post Issue | 11,29,48,625 shares |
| BSE Script Code / NSE Symbol | 544619 / SUDEEPPHRM |
| ISIN | INE0QPI01025 |
Sudeep Pharma IPO offers total 1,50,92,749 shares. Out of which 75,46,373 (50.00%) allocated to QIB, 30,18,550 (20.00%) allocated to QIB (Ex- Anchor), 22,63,913 (15.00%) allocated to NII 52,82,463 (35.00%) allocated to RII and 45,27,823 (30.00%) allocated to Anchor investors.
| Investor Category | Shares Offered | Max Allottees |
|---|---|---|
| QIB Shares Offered | 75,46,373 (50.00%) | NA |
| − Anchor Investor Shares Offered | 45,27,823 (30.00%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 30,18,550 (20.00%) | NA |
| NII (HNI) Shares Offered | 22,63,913 (15.00%) | NA |
| − bNII > ₹10L | 15,09,276 (10.00%) | 4,312 |
| − sNII < ₹10L | 7,54,637 (5.00%) | 2,156 |
| Retail Shares Offered | 52,82,463 (35.00%) | 2,11,298 |
| Total Shares Offered | 1,50,92,749 (100.00%) |
Investors can bid for a minimum of 25 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 25 | ₹14,825 |
| Retail (Max) | 13 | 325 | ₹1,92,725 |
| S-HNI (Min) | 14 | 350 | ₹2,07,550 |
| S-HNI (Max) | 67 | 1,675 | ₹9,93,275 |
| B-HNI (Min) | 68 | 1,700 | ₹10,08,100 |
Sudeep Pharma IPO raises ₹268.50 crore from anchor investors. Sudeep Pharma IPO Anchor bid date is November 20, 2025.
📝 Anchor Investors Letter (PDF)
| Bid Date | Thu, Nov 20, 2025 |
| Shares Offered | 45,27,823 |
| Anchor Portion (₹ Cr.) | 268.50 |
| Anchor lock-in period end date for 50% shares (30 Days) | Fri, Dec 26, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | Tue, Feb 24, 2026 |
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.
The company operates six manufacturing facilities with a combined production capacity of 50,000 MT, specializing in minerals such as calcium, iron, magnesium, zinc, potassium, and sodium
The company supplies more than 200 products to a diverse customer base across pharma, food, and nutrition sectors
The company has strong R&D capabilities with in-house labs and pilot-scale facilities focused on mineral salts and excipients.
Product Portfolio:
As of December 31, 2024, the company had 704 permanent employees.
Competitve Strengths:
Sudeep Pharma Ltd.'s revenue increased by 10% and profit after tax (PAT) rose by 4% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 922.26 | 717.17 | 513.87 | 420.11 |
| Total Income | 130.08 | 511.33 | 465.38 | 438.26 |
| Profit After Tax | 31.27 | 138.69 | 133.15 | 62.32 |
| EBITDA | 48.57 | 199.28 | 187.76 | 98.64 |
| NET Worth | 688.32 | 497.53 | 359.07 | 226.29 |
| Reserves and Surplus | 668.52 | 481.11 | 354.59 | 221.88 |
| Total Borrowing | 135.97 | 135.25 | 75.03 | 82.26 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I | 75.81 |
| 2 | General corporate purposes | 12.67 |
| KPI | Mar 31, 2025 |
|---|---|
| Debt/Equity | 0.20 |
| RoNW | 27.88% |
| PAT Margin | 27.63% |
| EBITDA Margin | 39.70% |
| Price to Book Value | 12.93 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 12.46 | 11.07 |
| P/E (x) | 47.61 | 53.55 |
| Promoter Holding | 89.37% | 76.15% |
| Market Cap | ₹6,697.85 Cr. |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | BRLMs fees and commissions (including underwriting commission, brokerage and selling commission) | 29.50 |
| 2 | Commission/ processing fee for SCSBs, Sponsor Banks and Bankers to the Offer. Brokerage, selling commission | 2.48 |
| 3 | Fees payable to the Registrar to the Offer | 0.01 |
| 4 | Fees payable to other intermediaries to the Offer, including but not limited to Statutory Auditor, independent chartered accountant, practicing company secretary and industry data provider | 3.86 |
| 5 | Fee payable to legal counsels | 8.40 |
| 6 | Listing fees, SEBI filing fees, upload fees, BSE and NSE processing fees, book building software fees and other regulatory expenses | 5.43 |
| 7 | Printing and distribution | 1.89 |
| 8 | Advertising and marketing expenses | 3.28 |
| 9 | Miscellaneous | 6.53 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹593.00 | ₹593.00 |
| Open | ₹733.95 | ₹730.00 |
| Low | ₹726.00 | ₹725.00 |
| High | ₹795.80 | ₹795.00 |
| Last Trade | ₹773.70 | ₹774.15 |
Lead Manager Reports
Sudeep Pharma IPO is a main-board IPO of 1,50,92,749 equity shares of the face value of ₹1 aggregating up to ₹895 Crores. The issue is priced at ₹593 per share. The minimum order quantity is 25.
The IPO opens on Fri, Nov 21, 2025, and closes on Tue, Nov 25, 2025.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Sudeep Pharma IPO using UPI as a payment gateway. Zerodha customers can apply in Sudeep Pharma IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Sudeep Pharma IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Sudeep Pharma IPO opens on Fri, Nov 21, 2025 and closes on Tue, Nov 25, 2025.
Sudeep Pharma IPO lot size is 25, and the minimum amount required for application is ₹14,825.
You can apply in Sudeep Pharma IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Sudeep Pharma IPO will be done on Wednesday, November 26, 2025, and the allotted shares will be credited to your demat account by Thu, Nov 27, 2025. Check the Sudeep Pharma IPO allotment status.
The Sudeep Pharma IPO listing date is on Fri, Nov 28, 2025.
